To verify whether RUFY3 is required for HOXD9 in the growth and metastasis of GC cells, we deployed a RUFY3 loss-of-function strategy in HOXD9-expressing AGS cells in vivo. The gene discussed is HOXD9; the disease is gastric cancer.